Zynlonta (Loncastuximab Tesirine): Antibody-Drug Conjugate Targeting CD19 in B-Cell Lymphoma
Overview
Zynlonta (loncastuximab tesirine-lpyl) is a CD19-directed antibody-drug conjugate (ADC) approved for relapsed/refractory (R/R) large B-cell lymphoma (LBCL) after ≥2 lines of systemic therapy, including DLBCL NOS, high-grade B-cell lymphoma, PMBCL, and FL grade 3B.
Structure & Mechanism
- Antibody: Humanized anti-CD19 monoclonal antibody (binds CD19 on B-cells).
- Linker: Valine-alanine protease-cleavable linker (stable in circulation, cleaved by lysosomal cathepsins).
- Payload: Pyrrolobenzodiazepine (PBD) dimer — DNA cross-linking agent (high potency, sequence-selective).
- DAR: ~3 drug molecules per antibody.
Multimodal Mechanism of Action
- Targeted delivery: Binds CD19 → internalization → lysosomal cleavage → PBD dimer release → DNA crosslinks → apoptosis.
- Bystander effect: Membrane-permeable payload kills neighboring CD19-negative tumor cells and stromal cells.
- Immunogenic cell death (ICD): Releases DAMPs (ATP, HMGB1, calreticulin) → activates dendritic cells → primes T-cell response.
- ADCC/ADCP: Fc domain engages NK cells/macrophages for antibody-dependent cytotoxicity/phagocytosis.
- T-cell modulation: Depletes immunosuppressive regulatory B-cells (Bregs); may enhance T-cell function.
Key Clinical Data (LOTIS-2, Phase 2)
- ORR: 48.3% (CR 23.8%) in heavily pretreated R/R LBCL (median 3 prior lines; 45% post-CAR-T).
- Median DOR: 10.3 months (CR: not reached).
- Median PFS: 4.9 months; OS: 9.5 months.
- CNS activity: Intracranial responses observed.
Dosing & Administration
- 150 µg/kg IV over 30 min every 3 weeks (cycle = 21 days).
- Premedication: Dexamethasone 10 mg IV (reduces edema/effusion), antihistamine, antipyretic.
- Prophylactic: Ursodiol 300 mg BID (reduces PBD-related hepatic toxicity), antiviral/PCP prophylaxis per institutional guidelines.
Key Toxicities
| Toxicity | Incidence (All Grade / Grade ≥3) | Management |
|---|---|---|
| Effusions (pleural, pericardial, ascites) | 29% / 8% | Dexamethasone premed; diuretics; thoracentesis; hold/resume at lower dose |
| Edema (peripheral, facial) | 30% / 3% | Dexamethasone; compression; diuretics |
| Elevated GGT / transaminases | 50%+ / 10% | Ursodiol prophylaxis; monitor LFTs q cycle; hold for Grade ≥3 |
| Neutropenia / thrombocytopenia | 30–40% / 15–20% | G-CSF support; dose delay/reduction |
| Fatigue, nausea, rash, infection | Common | Supportive care |
Unique Value
Zynlonta offers a non-chemotherapy, non-cellular option for patients who have exhausted standard therapies, including post-CAR-T. Its multimodal mechanism (direct kill + bystander + immune activation) and manageable safety profile (with prophylactic dexamethasone/ursodiol) make it a valuable addition to the R/R LBCL armamentarium.
Lymphoma - Related Articles
- Nutrition & Diet for Hodgkin's Lymphoma: A Comprehensive Guide
- Mediastinal Large B-Cell Lymphoma Treatments: Chemotherapy & Radiation
- Mantle Cell Lymphoma Treatment: Understanding Options & Approaches
- Lymphatic System: Anatomy, Function & Clinical Relevance
- Lymphocyte Circulation: Continuous Trafficking Between Blood and Lymphoid Organs
- Understanding Non-Hodgkin's Lymphoma: Symptoms and Immune System Impact
- Reactive Lymph Nodes: Causes, Typical Course, and Red Flags for Biopsy
